References
- Arenaviruses (Arenaviridae) | Viral Hemorrhagic Fevers (VHFs) | CDC [Internet]. [cited 2023 Apr 15]. Available from: https://www.cdc.gov/vhf/virus-families/arenaviridae.html
- Murphy HL, Ly H. Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments. Virulence. 2021 Dec;12(1):2989–3. PMCID: PMC8923068. doi: 10.1080/21505594.2021.2000290
- Blasdell KR, Duong V, Eloit M, et al. Evidence of human infection by a new mammarenavirus endemic to Southeastern Asia. Elife. 2016;5:e13135. PMCID: PMC4900801. doi: 10.7554/eLife.13135
- Luo XL, Lu S, Qin C, et al. Emergence of an ancient and pathogenic mammarenavirus. Emerg Microbes Infect. 2023 Dec 31;12(1):e2192816. Taylor & Francis. doi: 10.1080/22221751.2023.2192816
- Hallam SJ, Koma T, Maruyama J, et al. Review of mammarenavirus biology and replication. Front Microbiol. 2018;9 [cited 2023 Apr 15]. doi: 10.3389/fmicb.2018.01751
- Mariën J, Borremans B, Gryseels S, et al. No measurable adverse effects of Lassa, Morogoro and Gairo arenaviruses on their rodent reservoir host in natural conditions. Parasites Vectors. 2017 Apr 27;10(1):210. doi: 10.1186/s13071-017-2146-0
- Brisse ME, Ly H. Hemorrhagic fever-causing arenaviruses: lethal pathogens and potent immune suppressors. Front Immunol. 2019;10 [cited 2023 Apr 15]. doi: 10.3389/fimmu.2019.00372
- Carnec X, Mateo M, Page A, et al. A vaccine platform against arenaviruses based on a recombinant hyperattenuated mopeia virus expressing heterologous glycoproteins. J Virol. 2018 May 29;92(12):e02230–17. PMCID: PMC5974477
- Schieffelin J. Treatment of Arenavirus Infections. Curr Treat Options Infect Dis. 2015 Sep 1;7(3):261–270. doi: 10.1007/s40506-015-0058-0
- Li K, Lin XD, Wang W, et al. Isolation and characterization of a novel arenavirus harbored by Rodents and Shrews in Zhejiang province, China. Virology. 2015 Feb 1;476:37–42.